{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:04:45Z","timestamp":1793505885608,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,12,18]],"date-time":"2014-12-18T00:00:00Z","timestamp":1418860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.nmd.2014.12.004","type":"journal-article","created":{"date-parts":[[2014,12,20]],"date-time":"2014-12-20T03:17:09Z","timestamp":1419045429000},"page":"321-332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2941-2186","authenticated-orcid":false,"given":"Laura E.","family":"Case","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Bjartmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Casey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Charrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Clancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majed","family":"Dasouki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"DeArmey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khan","family":"Nedd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Nevins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Spigelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Tifft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2014.12.004_bib0010","doi-asserted-by":"crossref","first-page":"902","DOI":"10.2174\/138920111795542606","article-title":"Pompe disease: from new views on pathophysiology to innovative therapeutic strategies","volume":"12","author":"Parenti","year":"2011","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.nmd.2014.12.004_bib0015","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1357-4310(00)01694-4","article-title":"Towards a molecular therapy for glycogen storage disease type II (Pompe disease)","volume":"6","author":"Chen","year":"2000","journal-title":"Mol Med Today"},{"key":"10.1016\/j.nmd.2014.12.004_bib0020","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr Res"},{"key":"10.1016\/j.nmd.2014.12.004_bib0025","series-title":"Myozyme (alglucosidase alfa) [package insert]","year":"2012"},{"key":"10.1016\/j.nmd.2014.12.004_bib0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2014.12.004_bib0035","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet Med"},{"key":"10.1016\/j.nmd.2014.12.004_bib0040","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ajmg.c.31321","article-title":"Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations","volume":"160","author":"Case","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1016\/j.nmd.2014.12.004_bib0045","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gim.2012.44","article-title":"The emerging phenotype of long-term survivors with infantile Pompe disease","volume":"14","author":"Prater","year":"2012","journal-title":"Genet Med"},{"key":"10.1016\/j.nmd.2014.12.004_bib0050","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/dmcn.12120","article-title":"Criterion validity of the GMFM-66 item set and the GMFM-66 basal and ceiling approaches for estimating GMFM-66 scores","volume":"55","author":"Avery","year":"2013","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.nmd.2014.12.004_bib0055","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/1363849031000139298","article-title":"Development of a disease-specific disability instrument for Pompe disease","volume":"6","author":"Haley","year":"2003","journal-title":"Pediatr Rehabil"},{"key":"10.1016\/j.nmd.2014.12.004_bib0060","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1746-1340-15-4","article-title":"On the reliability and validity of manual muscle testing: a literature review","volume":"15","author":"Cuthbert","year":"2007","journal-title":"Chiropr Osteopat"},{"key":"10.1016\/j.nmd.2014.12.004_bib0065","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00005650-199303000-00006","article-title":"The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs","volume":"31","author":"McHorney","year":"1993","journal-title":"Med Care"},{"key":"10.1016\/j.nmd.2014.12.004_bib0070","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1300\/J006v21n02_06","article-title":"Using the gross motor function measure to evaluate motor development in children with Down syndrome","volume":"21","author":"G\u00e9mus","year":"2001","journal-title":"Phys Occup Ther Pediatr"},{"key":"10.1016\/j.nmd.2014.12.004_bib0075","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1469-8749.1998.tb12330.x","article-title":"Evaluating motor function in children with Down syndrome: validity of the GMFM","volume":"40","author":"Russell","year":"1998","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.nmd.2014.12.004_bib0080","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1469-8749.2012.04284.x","article-title":"Psychometric properties of functional mobility tools in hereditary spastic paraplegia and other childhood neurological conditions","volume":"54","author":"Adair","year":"2012","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.nmd.2014.12.004_bib0085","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/archneur.60.8.1130","article-title":"Reliability of 4 outcome measures in pediatric spinal muscular atrophy","volume":"60","author":"Iannaccone","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nmd.2014.12.004_bib0090","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1469-8749.2008.03150.x","article-title":"Outcome tools used for ambulatory children with cerebral palsy: responsiveness and minimum clinically important differences","volume":"50","author":"Oeffinger","year":"2008","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.nmd.2014.12.004_bib0095","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.apmr.2005.08.117","article-title":"Evaluating the responsiveness of 2 versions of the gross motor function measure for children with cerebral palsy","volume":"87","author":"Wang","year":"2006","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.nmd.2014.12.004_bib0100","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ymgme.2010.08.001","article-title":"Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy","volume":"101","author":"Raben","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2014.12.004_bib0105","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/WNO.0b013e3181ce162a","article-title":"Improvement of bilateral ptosis on higher dose enzyme replacement therapy in Pompe disease","volume":"30","author":"Yanovitch","year":"2010","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.nmd.2014.12.004_bib0110","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1750-1172-8-48","article-title":"Experimental designs for small randomised clinical trials: an algorithm for choice","volume":"8","author":"Cornu","year":"2013","journal-title":"Orphanet J Rare Dis"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096089661400724X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096089661400724X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:02:53Z","timestamp":1760774573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096089661400724X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S096089661400724X"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2014.12.004","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2014.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}